StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Tuesday. The firm issued a hold rating on the stock.

TherapeuticsMD Trading Up 1.8 %

Shares of TherapeuticsMD stock opened at $2.29 on Tuesday. TherapeuticsMD has a 1 year low of $1.95 and a 1 year high of $4.72. The company has a 50 day simple moving average of $2.31 and a two-hundred day simple moving average of $2.46.

Institutional Investors Weigh In On TherapeuticsMD

Hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. lifted its holdings in shares of TherapeuticsMD by 6.3% in the 1st quarter. Principal Financial Group Inc. now owns 123,319 shares of the company’s stock worth $47,000 after acquiring an additional 7,263 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of TherapeuticsMD by 22.6% in the 1st quarter. JPMorgan Chase & Co. now owns 255,249 shares of the company’s stock worth $97,000 after acquiring an additional 46,974 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of TherapeuticsMD by 4.8% in the 1st quarter. Rhumbline Advisers now owns 312,526 shares of the company’s stock worth $119,000 after acquiring an additional 14,372 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of TherapeuticsMD by 243.5% in the 1st quarter. Renaissance Technologies LLC now owns 3,147,599 shares of the company’s stock worth $1,196,000 after acquiring an additional 2,231,301 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of TherapeuticsMD by 0.3% in the 1st quarter. State Street Corp now owns 7,259,095 shares of the company’s stock worth $2,758,000 after acquiring an additional 19,452 shares during the last quarter. 30.74% of the stock is currently owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors.